# Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

- Source: PR Newswire
- Published: 2026-10-28T00:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-reports-positive-long-term-phase-iii-results-for-zemprocitinib-in-bdmards-inadequate-responders-with-moderate-to-severe-rheumatoid-arthritis-302920881.html
- Canonical: https://groundlevelnews.com/story/lynk-pharmaceuticals-reports-positive-long-term-phase-iii-results-for--ba4ed5/

HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._